Wilson Sonsini Goodrich & Rosati represented ImmunityBio in the transaction. ImmunityBio, Inc., a clinical-stage immunotherapy company announced an up to $320 million royalty financing and equity...
Oberland Capital’s $320 Million Investment in ImmunityBio
Nexo Therapeutics’ $60 Million Series A Financing Round
Wilson Sonsini Goodrich & Rosati advised Versant Ventures and New Enterprise Associates on the deal. Nexo Therapeutics (Nexo) announced it has emerged from stealth with $60 million...
Pacific Biosciences’ $201.25 Million Stock Offering
Wilson Sonsini advised Pacific Biosciences of California on the offering, and Davis Polk advised the representatives of the several underwriters involved. Pacific Biosciences of California Inc. announced...
Zenas BioPharma’s $118 Million Series B Financing
Wilson Sonsini Goodrich & Rosati advised lead investor Enavate Sciences and new investor Longitude Capital in the financing. Global pharmaceutical company Zenas BioPharma announced a $118...